Disruptive companies continue to affect ODs

Video

Disruptive companies are looking to make money by coming between the doctor and the patient, especially in the contact lens market. Jeff Sonsino, OD, FAAO, suggests private practice ODs have tools at their disposal to help them compete.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Subscribe Now!
Recent Videos
Dr Paul Karpecki discusses atropine formulation from Sydnexis following NDA acceptance by FDA
OptiLIFT in action: Dr. Julie McLaughlin's experience with the new device
Dr. Mile Brujic discusses a case series on a novel gel for lacrimal occlusion.
What was the biggest innovation in eye care in 2024?
Jacob R. Lang, OD, FAAO
Related Content
FDA issues CRL for extended dosing regiment for Eylea HD for wet AMD, DME, and DR - Image credit: Adobe Stock / ©Michele Ursi

Regeneron announces FDA issues CRL for aflibercept 8 mg (Eylea HD) sBLA

Martin David Harp, Editor, Ophthalmology Times;Hattie Hayes;Kassi Filkins, Editor
April 21st 2025
Article
FDA grants 510(k) clearance to BVI Medical for laser endoscopic surgical system for glaucoma - Image credit: Adobe Stock / ©monticellllo

BVI Medical receives 510(k) clearance FDA for laser endoscopic surgical system for glaucoma

Sydney M Crago, Editor, Modern Retina;Emily Kaiser Maharjan, Assistant Managing Editor
April 17th 2025
Article
FDA accepts sBLA for Eylea HD for priority review by FDA - Image credit: ©Milos—stock.adobe.com

Regeneron’s sBLA for Eylea HD accepted for priority review by FDA

Martin David Harp, Editor, Ophthalmology Times
April 17th 2025
Article
Opus Genetics issues 1-month pediatric gene therapy results - Image credit: Adobe Stock / ©Andrii Yalanskyi

Opus Genetics issues 1-month pediatric gene therapy results

Lynda Charters
April 9th 2025
Article
FDA accepts updated BLA from Outlook Therapeutics for ONS-5019 for wet AMD - Image credit: Adobe Stock / ©Have a nice day

FDA accepts updated biologics license application from Outlook Therapeutics for ONS-5010 for the treatment of wet AMD

Martin David Harp, Editor, Ophthalmology Times
April 9th 2025
Article
Opthea discontinues COAST and ShORe clinical trials for wet AMD - Image credit: Adobe Stock / ©Phimwilai

Opthea discontinues COAST and ShORe trials in wet AMD

Martin David Harp, Editor, Ophthalmology Times
March 31st 2025
Article
© 2025 MJH Life Sciences

All rights reserved.